Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

NCT02577016 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

141

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Sitagliptin
DRUG: Placebo
DRUG: Ipragliflozin

Sponsor

Merck Sharp & Dohme LLC